2. Provided, That the execution of the above punishment shall be suspended for two years from the date this judgment becomes final and conclusive;

3.

On July 2006, the Defendant: (a) purchased one name name D, E, and forged non-cogra and Simalce, and openly conspired to divide profits accrued from the following market in Korea; (b) D, in China, opened and advertised the sale of forged non-cogna and Simalcee on the Internet homepage; and (c) purchased and deliver fake and Simalcee to the Republic of Korea; (d) the Defendant invested 15 million won in purchasing fake and Simcecee; (e) managed the Internet homepage; (e) notified E of the details of the orders to be consulted and ordered by the buyer; and (e) E shared that the details of orders from the Defendant in Korea were received from the buyer and delivery of fake and Simcee to buyers.

1. From September 5, 2006 to November 22, 2006 of the same year, the Defendant violated the Trademark Act: (a) the Defendant received orders from the buyers on its Internet homepage (F) from the buyers; and (b) the Defendant conspired with the Korean Intellectual Property Office of the United States of America for the sale of fake and professional e-mail drugs, etc. for treatment of visual disorder disorder, etc., registered with the Korean Intellectual Property Office as designated goods by the following: (c) the Defendant: (d) the Defendant: (d) the Defendant: (d) the counterfeit and professional e-mail in the United States of America; (d) the Defendant conspired with the Korean Intellectual Property Office of U.S. on the designated goods of the Korea; (e) the trademark right holder’s trademark registration was forged at his discretion, 2,263,100,500,500,000,000 won and e-mails; and (e) the trademark right holder’s trademark registration was forged at his discretion, e.g., and 537.

2. The defendants who violate the Pharmaceutical Affairs Act shall be D and E.